Literature DB >> 32158806

Novel oral anticoagulant induced upper limb haematoma: A case report.

Nanda Kandamany1, Heather Tan1.   

Abstract

The development of novel oral anticoagulant agents (NOACs) such as dabigatran, rivaroxaban, apixaban and edoxaban has given patients better treatment alternatives to aspirin, clopidogrel, heparin and warfarin, mainly for stroke prophylaxis in patients with non-valvular atrial fibrillation (NVAF), prophylaxis/treatment of venous thromboembolism (VTE) and also for the secondary prophylaxis of acute coronary syndromes. These agents are gaining in popularity due to their more stable pharmacokinetic profile, fewer drug interactions, as well as eliminating the need for routine monitoring. NOAC induced haematomas of the upper limb are rare and there is no real consensus on management. We present a case of a 70-year-old male on rivaroxaban who developed a delayed onset intramuscular forearm haematoma after a simple fall onto his left arm. Simple elevation of the limb was successful in leading to resolution of symptoms. As these agents increase in popularity, clinicians need to be more aware of potential risks of treatment and subsequent management. Crown
Copyright © 2017 Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons.

Entities:  

Keywords:  Haematoma; NOAC; NOAC induced haematoma; Rivaroxaban; Upper limb

Year:  2018        PMID: 32158806      PMCID: PMC7061690          DOI: 10.1016/j.jpra.2017.08.008

Source DB:  PubMed          Journal:  JPRAS Open        ISSN: 2352-5878


Introduction

The development of novel oral anticoagulant agents (NOACs) such as dabigatran, rivaroxaban, apixaban and edoxaban has given patients better treatment alternatives to aspirin, clopidogrel, heparin and warfarin, mainly for stroke prophylaxis in patients with non-valvular atrial fibrillation (NVAF), prophylaxis/treatment of venous thromboembolism (VTE) and also for the secondary prophylaxis of acute coronary syndromes. These agents have a more stable pharmacokinetic profile, have fewer drug interactions, and can be administered in a standard dose without the need for routine monitoring, however, the risk of bleeding and haematoma formation remain. We present a case of a 70-year-old male on rivaroxaban who developed a delayed onset intramuscular forearm haematoma after a fall onto his left arm. This case is of interest due to the unusual location of the haematoma and associated symptoms of ulnar nerve compression which are most likely due to previous ulnar nerve transposition. To our knowledge, this is the first report of a NOAC induced upper limb haematoma.

Case presentation

A 70-year old-male on anticoagulant therapy presented with pain and numbness in the ulnar nerve distribution of his left arm six days after a simple fall. The pain initially affected his wrist but gradually extended up to his elbow along with marked bruising. He also noticed progressive paraesthesia in the ulnar nerve distribution affecting his ring and little fingers. His motor function was not affected. His past medical history included, bilateral ulnar nerve decompression and transposition, bilateral carpal tunnel decompression, chronic back pain and atrial fibrillation managed with Xarelto (rivaroxaban). An MRI confirmed a 20×20×34 mm focal haematoma within the flexor digitorum superficialis muscle at the junction of the middle and distal thirds of the forearm (Figures 1 and 2). There was no evidence of ulnar nerve compression. No fracture was seen on x-ray. His coagulation profile revealed an elevated APTT (39 s) and PT (15.4 s). His rivaroxaban was ceased and his arm was elevated. The bruising improved after elevation and he was discharged after five days with a tubigrip. He was restarted on rivaroxaban after two weeks and his symptoms of paraesthesia resolved six weeks following discharge.
Figure 1

Forearm MRI in the axial plane, showing a focal haematoma (a) in the flexor digitorum superficialis muscle (b).

Figure 2

Forearm MRI in the coronal plane showing the haematoma (a) within the flexor digitorum superficialis at the junction of the middle and distal thirds of the forearm.

Forearm MRI in the axial plane, showing a focal haematoma (a) in the flexor digitorum superficialis muscle (b). Forearm MRI in the coronal plane showing the haematoma (a) within the flexor digitorum superficialis at the junction of the middle and distal thirds of the forearm.

Discussion

Haemorrhage and haematoma formation are significant complications of anticoagulant use and it is essential to weigh up the risk of bleeding in any patient being considered for anticoagulant therapy. A recent meta-analysis showed that NOACs had better efficacy compared to warfarin in terms of stroke and haemorrhage risk reduction, but had a similar overall bleeding risk and higher risk of gastrointestinal tract bleeding due to direct caustic damage and inhibition of gut mucosal healing. Bleeding can be traumatic, spontaneous or iatrogenic. In a cohort study of 1082 patients on rivaroxaban therapy, traumatic bleeding was uncommon with 170 patients suffering from trauma related bleeding with the remaining bleeds being spontaneous or following surgery. Minor trauma can lead to muscle haematomas with anticoagulant use although upper limb haematomas are rare. Lower limb haematomas are far more commonly reported in anticoagulated patients. A study on injury patterns in the geriatric population found the most common locations were the head and lower extremity with upper extremity injuries making up less than 1%. This explains the prevalence of lower limb haematomas as the majority of anticoagulated patients are elderly and falls are a common mechanism of injury in this age group. NOAC induced intramuscular haematomas are rare and to our knowledge, this is the first reported case of an isolated flexor digitorum superficialis haematoma. Our case is also unusual as there were symptoms of ulnar nerve paraesthesia without corresponding radiological evidence. It was therefore hypothesised that following transposition, the ulnar nerve would be running in a more superficial course and thus more susceptible to minimal extrinsic compression. Our patients' symptoms also resolved on elevation of the limb without the need for surgical intervention. Little evidence exists around the management of NOAC induced traumatic haematoma however consensus shows that even in the absence of specific antidotes, NOAC related bleeds can usually be managed non-operatively with cessation of the anticoagulant, fluids and packed red cells.7, 8, 9 We utilised non-operative measures in this case as there was no evidence of continuing haemorrhage, worsening nerve compression symptoms or compartment syndrome requiring urgent surgical intervention. Simple elevation of the limb was successful leading to spontaneous resolution of symptoms.

Conclusion

Our case highlights the importance of remaining aware of the complications of NOAC therapy. With an increasing number of patients being placed on NOAC therapy, more information is needed on the safety of long term therapy. Even though rare, minor trauma can result in significant bleeding and haematoma formation necessitating the need for urgent surgical intervention.

Conflicts of interest

None.

Funding

No funding was received for the publication of this work.

Ethics approval

Not applicable.
  9 in total

1.  Acute compartment syndromes resulting from anticoagulant treatment.

Authors:  S M Hay; M J Allen; M R Barnes
Journal:  BMJ       Date:  1992-12-12

2.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

3.  Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study.

Authors:  Yan Xu; Sam Schulman; Dar Dowlatshahi; Anne M Holbrook; Christopher S Simpson; Lois E Shepherd; Philip S Wells; Antonio Giulivi; Tara Gomes; Muhammad Mamdani; Wayne Khuu; Eliot Frymire; Ana P Johnson
Journal:  Chest       Date:  2017-02-17       Impact factor: 9.410

4.  Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).

Authors:  Benjamin A Steinberg; DaJuanicia N Simon; Laine Thomas; Jack Ansell; Gregg C Fonarow; Bernard J Gersh; Peter R Kowey; Kenneth W Mahaffey; Eric D Peterson; Jonathan P Piccini
Journal:  Am J Cardiol       Date:  2017-03-28       Impact factor: 2.778

5.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman
Journal:  Lancet       Date:  2013-12-04       Impact factor: 79.321

6.  A Comprehensive Investigation of Comorbidities, Mechanisms, Injury Patterns, and Outcomes in Geriatric Blunt Trauma Patients.

Authors:  Carlos V R Brown; Kevin Rix; Amanda L Klein; Brent Ford; Pedro G R Teixeira; Jayson Aydelotte; Ben Coopwood; Sadia Ali
Journal:  Am Surg       Date:  2016-11-01       Impact factor: 0.688

Review 7.  Direct Oral Anticoagulants in Emergency Trauma Admissions.

Authors:  Marc Maegele; Oliver Grottke; Herbert Schöchl; Oliver A Sakowitz; Michael Spannagl; Jürgen Koscielny
Journal:  Dtsch Arztebl Int       Date:  2016-09-05       Impact factor: 5.594

8.  New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.

Authors:  H Tran; J Joseph; L Young; S McRae; J Curnow; H Nandurkar; P Wood; C McLintock
Journal:  Intern Med J       Date:  2014-06       Impact factor: 2.048

Review 9.  Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.

Authors:  Ka-Shing Cheung; Wai K Leung
Journal:  World J Gastroenterol       Date:  2017-03-21       Impact factor: 5.742

  9 in total
  1 in total

1.  Non-Traumatic Intramuscular Hip Hematoma in a Cirrhotic Patient With Hepatocellular Carcinoma and Portal Vein Thrombosis Treated With Sorafenib and Low Molecular Weight Heparin.

Authors:  Christos Sotiropoulos; Konstantinos Thomopoulos
Journal:  Cureus       Date:  2021-05-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.